Key points are not available for this paper at this time.
A genomic predictor combining ER status, predicted chemoresistance, predicted chemosensitivity, and predicted endocrine sensitivity identified patients with high probability of survival following taxane and anthracycline chemotherapy.
Christos Hatzis (Tue,) studied this question.